Subtopic Deep Dive
Therapeutic Targets in Metastatic Lung Carcinomas
Research Guide
What is Therapeutic Targets in Metastatic Lung Carcinomas?
Therapeutic targets in metastatic lung carcinomas are molecular markers and pathways identified in non-small cell lung cancer (NSCLC) metastases for targeted therapies and immunotherapies.
Research focuses on circulating tumor cells (CTCs) as prognostic biomarkers in NSCLC, with detection challenges due to epithelial-mesenchymal transition (EMT). Key studies validate CTCs for predicting treatment response (Krebs et al., 2011, 863 citations). EMT enables CTC escape from EpCAM-based detection (Gorges et al., 2012, 552 citations). Over 250 papers explore these targets via OpenAlex.
Why It Matters
CTCs in metastatic NSCLC predict progression-free survival and guide therapy selection, as shown in Krebs et al. (2011) where CTC detection correlated with poor outcomes. EMT markers on CTCs inform resistance mechanisms, enabling combination therapies (Armstrong et al., 2011). These targets improve survival in advanced lung cancer patients lacking validated biomarkers.
Key Research Challenges
EMT-Mediated CTC Detection Failure
CTCs undergoing EMT lose epithelial markers like EpCAM, evading standard detection protocols. Gorges et al. (2012) showed reduced CTC capture in mesenchymal states. Multimarker assays are needed for comprehensive profiling.
Prognostic Validation in NSCLC
CTCs require validation as biomarkers for NSCLC treatment response. Krebs et al. (2011) detected CTCs but noted variability in prognostic significance. Standardization across patient cohorts remains unresolved.
Translating CTCs to Lung Targets
Linking CTC profiles to actionable therapeutic targets in lung metastases is limited. Armstrong et al. (2011) identified mixed epithelial-mesenchymal markers in CTCs. Clinical trials for EMT-targeted drugs are scarce.
Essential Papers
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem et al. · 2022 · Journal of the National Comprehensive Cancer Network · 1.6K citations
Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histolog...
Epithelial Mesenchymal Transition in Tumor Metastasis
Vivek Mittal · 2018 · Annual Review of Pathology Mechanisms of Disease · 1.5K citations
Metastasis is the major cause of cancer-related deaths; therefore, the prevention and treatment of metastasis are fundamental to improving clinical outcomes. Epithelial mesenchymal transition (EMT)...
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Andrew G. Nicholson, Ming‐Sound Tsao, Mary Beth Beasley et al. · 2021 · Journal of Thoracic Oncology · 1.3K citations
Chemotherapy for advanced gastric cancer
Dorothea Wagner, Nicholas Syn, Markus Moehler et al. · 2017 · Cochrane Database of Systematic Reviews · 1.3K citations
Chemotherapy improves survival (by an additional 6.7 months) in comparison to BSC, and combination chemotherapy improves survival (by an additional month) compared to single-agent 5-FU. Testing all...
Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Massimo Cristofanilli, Daniel F. Hayes, G. Thomas Budd et al. · 2005 · Journal of Clinical Oncology · 1.1K citations
Purpose Metastatic breast cancer (MBC) is incurable; its treatment is palliative. We investigated whether the presence of circulating tumor cells (CTCs) predicts treatment efficacy, progression-fre...
Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer
Matthew Krebs, Robert Szczepaniak‐Sloane, Lynsey Priest et al. · 2011 · Journal of Clinical Oncology · 863 citations
Purpose Lung cancer is the leading cause of cancer-related death worldwide. Non–small-cell lung cancer (NSCLC) lacks validated biomarkers to predict treatment response. This study investigated whet...
Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers
Andrew J. Armstrong, Matthew S. Marengo, Sebastian Oltean et al. · 2011 · Molecular Cancer Research · 647 citations
Abstract During cancer progression, malignant cells undergo epithelial-mesenchymal transitions (EMT) and mesenchymal-epithelial transitions (MET) as part of a broad invasion and metastasis program....
Reading Guide
Foundational Papers
Start with Krebs et al. (2011) for CTC prognostic validation in NSCLC, then Cristofanilli et al. (2005) for metastatic cancer principles, and Gorges et al. (2012) for EMT detection limits.
Recent Advances
Nicholson et al. (2021) for updated lung tumor classification impacting targets; Mittal (2018) for EMT in metastasis.
Core Methods
CTC enumeration via CellSearch (EpCAM-based); survival analysis with Kaplan-Meier; EMT marker IHC on CTCs (Krebs et al., 2011; Gorges et al., 2012).
How PapersFlow Helps You Research Therapeutic Targets in Metastatic Lung Carcinomas
Discover & Search
Research Agent uses searchPapers and exaSearch to find NSCLC CTC studies like Krebs et al. (2011), then citationGraph reveals 863 citing papers on therapeutic targets. findSimilarPapers expands to EMT in lung metastases from Gorges et al. (2012).
Analyze & Verify
Analysis Agent applies readPaperContent to extract CTC thresholds from Krebs et al. (2011), verifies claims with CoVe against Nicholson et al. (2021), and runs PythonAnalysis for survival curve meta-analysis using pandas on extracted data. GRADE grading scores evidence as moderate for CTC prognostics.
Synthesize & Write
Synthesis Agent detects gaps in EMT-targeted therapies via contradiction flagging between Armstrong et al. (2011) and recent classifiers. Writing Agent uses latexEditText, latexSyncCitations for Krebs et al., and latexCompile for reports. exportMermaid visualizes CTC-EMT pathway diagrams.
Use Cases
"Analyze survival data from CTC studies in metastatic NSCLC"
Research Agent → searchPapers('Krebs 2011 CTC NSCLC') → Analysis Agent → runPythonAnalysis(pandas meta-analysis of PFS/OS from 5 papers) → statistical p-values and Kaplan-Meier plots.
"Draft LaTeX review on EMT targets in lung cancer metastases"
Synthesis Agent → gap detection(EMT therapies) → Writing Agent → latexEditText(structure review) → latexSyncCitations(Krebs, Gorges) → latexCompile → PDF with figures.
"Find code for CTC detection analysis in lung cancer papers"
Research Agent → paperExtractUrls(Krebs 2011) → paperFindGithubRepo → githubRepoInspect → runnable R scripts for CTC enumeration shared with researcher.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ NSCLC CTC papers) → citationGraph → GRADE grading → structured report on targets. DeepScan applies 7-step analysis with CoVe checkpoints to verify Krebs et al. (2011) claims against Nicholson et al. (2021). Theorizer generates hypotheses on EMT inhibitors from Gorges et al. (2012) and Armstrong et al. (2011).
Frequently Asked Questions
What defines therapeutic targets in metastatic lung carcinomas?
Molecular markers like CTCs and EMT-related proteins in NSCLC metastases for targeted therapies (Krebs et al., 2011).
What methods detect CTCs in NSCLC?
EpCAM-based protocols, but EMT causes escape; multimarker approaches improve yield (Gorges et al., 2012).
What are key papers on lung CTC targets?
Krebs et al. (2011, 863 citations) validates CTC prognosis in NSCLC; Nicholson et al. (2021) updates tumor classification.
What open problems exist?
Standardizing CTC assays for EMT states and linking to lung-specific therapies (Armstrong et al., 2011).
Research Metastasis and carcinoma case studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Therapeutic Targets in Metastatic Lung Carcinomas with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers